Form 4: Clover Health CEO Jamie Reynoso Sells Shares

Sentiment:

Statement of Changes in Beneficial Ownership


Clover Health Investments, Corp. CEO Jamie Reynoso sold 7,289 shares of Class A Common Stock via a 10b5-1 trading plan.

Summary

  • Jamie L. Reynoso, CEO of Medicare Advantage at Clover Health, sold 7,289 shares of Class A Common Stock.
  • The transaction occurred on June 11, 2026, at a weighted average price of $4.91 per share.
  • The sale was executed under a pre-established Rule 10b5-1 trading plan adopted on March 12, 2026.
  • Following the transaction, the reporting person retains beneficial ownership of 2,849,921 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed under a pre-planned 10b5-1 arrangement, which is standard practice for corporate officers.

Positives

  • The sale was conducted through a pre-planned Rule 10b5-1 trading plan, which is a standard mechanism for executives to sell shares without triggering insider trading concerns.

Negatives

  • The sale represents a reduction in the executive's direct equity stake in the company.

Risks

  • Market perception of executive selling can sometimes lead to short-term downward pressure on the stock price.

Future Outlook

No forward-looking guidance or strategic outlook was provided in this filing.

Industry Context

StockSavvy.ai notes that executive stock sales via 10b5-1 plans are routine corporate governance activities and generally do not signal a change in company fundamentals or management confidence.

Comparison to Industry Standards

  • The use of Rule 10b5-1 plans is the industry standard for executives at publicly traded companies to manage personal liquidity while maintaining compliance with SEC regulations.

Stakeholder Impact

  • Minimal impact on shareholders as the sale was pre-planned and represents a small fraction of the executive's total holdings.

Next Steps

  • No future actions or milestones were disclosed in this filing.

Key Dates

DateDescription
03/12/2026Date the Rule 10b5-1 trading plan was adopted.
06/11/2026Date of the reported stock sale transaction.

Keywords

Clover Health, CLOV, Insider Trading, Form 4, Medicare Advantage, Executive Compensation

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.